These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24528318)

  • 1. Ivacaftor imaging response in cystic fibrosis.
    Hoare S; McEvoy S; McCarthy CJ; Kilcoyne A; Brady D; Gibney B; Gallagher CG; McKone EF; Dodd JD
    Am J Respir Crit Care Med; 2014 Feb; 189(4):484. PubMed ID: 24528318
    [No Abstract]   [Full Text] [Related]  

  • 2. CT imaging of pediatric patients with cystic fibrosis on ivacaftor therapy.
    Hayes D; Long FR; McCoy KS; Sheikh SI
    Lung; 2014 Oct; 192(5):823-4. PubMed ID: 25099273
    [No Abstract]   [Full Text] [Related]  

  • 3. Cystic fibrosis, ivacaftor, and the Arg117His-CFTR mutation.
    Accurso FJ
    Lancet Respir Med; 2015 Jul; 3(7):498-9. PubMed ID: 26170070
    [No Abstract]   [Full Text] [Related]  

  • 4. Cystic fibrosis drug Vertex's latest triumph.
    Ledford H
    Nat Biotechnol; 2012 Mar; 30(3):201-2. PubMed ID: 22398597
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutation-specific therapy in cystic fibrosis: the earlier, the better.
    Tümmler B
    Lancet Respir Med; 2013 Oct; 1(8):591-592. PubMed ID: 24461654
    [No Abstract]   [Full Text] [Related]  

  • 6. Cystic fibrosis drug is not cost effective, says NICE.
    Gulland A
    BMJ; 2016 Jun; 353():i3409. PubMed ID: 27325384
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor.
    Chassagnon G; Hubert D; Fajac I; Burgel PR; Revel MP;
    Eur Respir J; 2016 Jul; 48(1):249-52. PubMed ID: 27230445
    [No Abstract]   [Full Text] [Related]  

  • 8. Precision Medicine: At What Price?
    Ferkol T; Quinton P
    Am J Respir Crit Care Med; 2015 Sep; 192(6):658-9. PubMed ID: 26207804
    [No Abstract]   [Full Text] [Related]  

  • 9. Ivacaftor (Kalydeco) for cystic fibrosis.
    Med Lett Drugs Ther; 2012 Apr; 54(1388):29-30. PubMed ID: 22499233
    [No Abstract]   [Full Text] [Related]  

  • 10. Resolution of cystic fibrosis-related diabetes with ivacaftor therapy.
    Hayes D; McCoy KS; Sheikh SI
    Am J Respir Crit Care Med; 2014 Sep; 190(5):590-1. PubMed ID: 25171312
    [No Abstract]   [Full Text] [Related]  

  • 11. Ivacaftor for patients with cystic fibrosis.
    Wainwright CE
    Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ivacaftor in a G551D homozygote with cystic fibrosis.
    Harrison MJ; Murphy DM; Plant BJ
    N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
    [No Abstract]   [Full Text] [Related]  

  • 13. Resolution of Intestinal Histopathology Changes in Cystic Fibrosis after Treatment with Ivacaftor.
    Safe M; Gifford AJ; Jaffe A; Ooi CY
    Ann Am Thorac Soc; 2016 Feb; 13(2):297-8. PubMed ID: 26848606
    [No Abstract]   [Full Text] [Related]  

  • 14. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation.
    Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
    J Cyst Fibros; 2015 Jan; 14(1):84-9. PubMed ID: 25049054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of hepatic steatosis in cystic fibrosis with ivacaftor therapy.
    Hayes D; Warren PS; McCoy KS; Sheikh SI
    J Pediatr Gastroenterol Nutr; 2015 May; 60(5):578-9. PubMed ID: 25688481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of sinus disease in cystic fibrosis with ivacaftor therapy.
    Hayes D; McCoy KS; Sheikh SI
    Am J Respir Crit Care Med; 2014 Aug; 190(4):468. PubMed ID: 25127305
    [No Abstract]   [Full Text] [Related]  

  • 17. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
    Heltshe SL; Mayer-Hamblett N; Burns JL; Khan U; Baines A; Ramsey BW; Rowe SM;
    Clin Infect Dis; 2015 Mar; 60(5):703-12. PubMed ID: 25425629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modifying disease in cystic fibrosis: current and future therapies on the horizon.
    Ong T; Ramsey BW
    Curr Opin Pulm Med; 2013 Nov; 19(6):645-51. PubMed ID: 24048086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach].
    Desch M
    Med Monatsschr Pharm; 2016 Jan; 39(1):42-4. PubMed ID: 26975180
    [No Abstract]   [Full Text] [Related]  

  • 20. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation.
    Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
    Clin Otolaryngol; 2015 Feb; 40(1):16-21. PubMed ID: 25145599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.